We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+4.9%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$265M
AUM Growth
+$37.5M
(+17%)
Cap. Flow
+$34M
Cap. Flow
% of AUM
12.86%
Top 10 Holdings %
Top 10 Hldgs %
9.25%
Holding
421
New
24
Increased
206
Reduced
145
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DT Midstream
DTM
|
+$1.85M |
| 2 |
Delek US
DK
|
+$898K |
| 3 |
ScottsMiracle-Gro
SMG
|
+$843K |
| 4 |
Valero Energy
VLO
|
+$783K |
| 5 |
FMC
FMC
|
+$709K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
COR
Coresite Realty Corporation
COR
|
+$1.67M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$601K |
| 3 |
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
|
+$551K |
| 4 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
+$448K |
| 5 |
Travere Therapeutics
TVTX
|
+$434K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 22.39% |
| 2 | Healthcare | 18.38% |
| 3 | Energy | 15.88% |
| 4 | Materials | 14.07% |
| 5 | Utilities | 13.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Incyte
INCY
$23.7B
| $398K | 0.15% |
5,423
-113
| -2% | -$7.62K |
|
|
SGEN
152
DELISTED
Seagen Inc. Common Stock
SGEN
| $398K | 0.15% |
2,575
-350
| -12% | -$58.6K |
|
153
Ironwood Pharmaceuticals
IRWD
$644M
| $397K | 0.15% |
34,062
-6,633
| -16% | -$81.4K |
|
154
BioMarin Pharmaceuticals
BMRN
$11.6B
| $396K | 0.15% |
4,486
-1,058
| -19% | -$87.3K |
|
155
Nektar Therapeutics
NKTR
$2.41B
| $396K | 0.15% |
1,956
+232
| +13% | +$50.3K |
|
|
EFR
156
Eaton Vance Senior Floating-Rate Fund
EFR
$314M
| $394K | 0.15% |
26,680
-5,643
| -17% | -$84.5K |
|
157
Amgen
AMGN
$203B
| $391K | 0.15% |
1,740
-151
| -8% | -$31.9K |
|
158
Sarepta Therapeutics
SRPT
$1.68B
| $391K | 0.15% |
4,345
-966
| -18% | -$82.6K |
|
159
Vertex Pharmaceuticals
VRTX
$122B
| $390K | 0.15% |
1,778
-572
| -24% | -$111K |
|
160
Oaktree Specialty Lending
OCSL
$1.04B
| $389K | 0.15% |
17,369
-1,412
| -8% | -$31.3K |
|
161
ADC Therapeutics
ADCT
$145M
| $388K | 0.15% |
19,193
-535
| -3% | -$12.9K |
|
162
Biogen
BIIB
$29.5B
| $387K | 0.15% |
1,612
+481
| +43% | +$124K |
|
|
EFT
163
Eaton Vance Floating-Rate Income Trust
EFT
$284M
| $386K | 0.15% |
25,578
-3,618
| -12% | -$53.9K |
|
|
EVF
164
Eaton Vance Senior Income Trust
EVF
$90.1M
| $385K | 0.15% |
57,103
-4,521
| -7% | -$31.2K |
|
165
Invesco Senior Income Trust
VVR
$456M
| $385K | 0.15% |
88,956
-13,742
| -13% | -$61.1K |
|
166
Gilead Sciences
GILD
$162B
| $383K | 0.14% |
5,274
-1,436
| -21% | -$98.9K |
|
167
Neurocrine Biosciences
NBIX
$17.7B
| $383K | 0.14% |
4,497
-97
| -2% | -$8.92K |
|
168
Ultragenyx Pharmaceutical
RARE
$2.65B
| $383K | 0.14% |
4,550
+100
| +2% | +$8.14K |
|
|
YMAB
169
DELISTED
Y-mAbs Therapeutics
YMAB
| $383K | 0.14% |
23,646
+11,068
| +88% | +$237K |
|
170
Agios Pharmaceuticals
AGIO
$2.2B
| $379K | 0.14% |
11,541
+3,692
| +47% | +$149K |
|
171
Insmed
INSM
$22.7B
| $378K | 0.14% |
13,869
-1,392
| -9% | -$39.8K |
|
172
Acadia Pharmaceuticals
ACAD
$4.35B
| $377K | 0.14% |
16,172
-613
| -4% | -$12.3K |
|
173
Ionis Pharmaceuticals
IONS
$9.25B
| $374K | 0.14% |
12,296
+194
| +2% | +$6.11K |
|
174
Zai Lab
ZLAB
$2.1B
| $373K | 0.14% |
5,933
+3,241
| +120% | +$275K |
|
175
Barings BDC
BBDC
$868M
| $367K | 0.14% |
33,326
-1,625
| -5% | -$17.9K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q4 2021 Portfolio in Review
As of Q4 2021, Virtus ETF Advisers held 421 positions worth $265M, up 17% from $227M the previous quarter. Its ten largest holdings account for 9.2% of the portfolio.
Virtus ETF Advisers deployed $34M of net new capital in Q4 2021, opening 24 new positions and adding to 206 existing holdings. Its largest new stake was Invivyd: 22,625 shares worth $164K.
By sector, the portfolio is most concentrated in Real Estate at 22% of assets, up from 20% a quarter earlier, followed by Healthcare and Energy.
On the sell side, the largest reduction was Travere Therapeutics, an estimated $434K trimmed.
- Virtus ETF Advisers's largest Q4 2021 buy was Invivyd: 22,625 shares worth $164K.
- Virtus ETF Advisers added most to DT Midstream in Q4 2021, an estimated $1.85M increase.
- Virtus ETF Advisers's biggest Q4 2021 reduction was Travere Therapeutics, cutting an estimated $434K.
- Virtus ETF Advisers fully exited Coresite Realty Corporation in Q4 2021, selling an estimated $1.67M.
- Virtus ETF Advisers's ten largest holdings make up 9.2% of its $265M portfolio in Q4 2021.
- Virtus ETF Advisers opened 24 new positions and closed 45 in Q4 2021.
- Virtus ETF Advisers's portfolio value rose 17% quarter-over-quarter to $265M.
Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.